» Articles » PMID: 37609466

Leveraging Implementation Science in the Treatment of Tobacco Use Disorder

Overview
Journal Mo Med
Specialty General Medicine
Date 2023 Aug 23
PMID 37609466
Authors
Affiliations
Soon will be listed here.
Abstract

The tobacco use disorder field has an armamentarium of approaches to help people quit smoking: medication-based treatment for tobacco use, digital therapeutics for just-intime behavioral interventions, genetic and metabolic biomarkers to guide tobacco treatment, to name a few. Whether the treatment approach is old or new, an underlying truth remains: the benefit is only as great as the extent to which these treatment approaches reach individuals who need them most and prove effective and feasible to implement in real-world settings. Further, certain treatments tend to be used more robustly in practice, namely, those that address a great need yet are low in cost, burden, and risk of clinical harms. This is where implementation science comes in, providing guidance on how best to get effective treatments adopted and used in clinical and community settings. Implementation science holds the keys to the uptake and routine use of evidence-based treatments and should be more fully leveraged in the tobacco use disorder field. At the same time, disruptive technologies in treatment are breaking new ground, pushing the field of implementation science to build a bigger "toolbox" of ways to improve access and quality of treatment in an ever-evolving landscape. In this paper, we underscore this synergy between tobacco treatment and implementation science. We spotlight emerging trends in tobacco use, effective and emerging treatment approaches for tobacco use, and ways that implementation science intersects with the current and evolving landscape of tobacco use and substance use disorder more broadly.

References
1.
Chen L, Baker T, Brownson R, Carney R, Jorenby D, Hartz S . Smoking Cessation and Electronic Cigarettes in Community Mental Health Centers: Patient and Provider Perspectives. Community Ment Health J. 2016; 53(6):695-702. PMC: 5449258. DOI: 10.1007/s10597-016-0065-8. View

2.
Berry N, Lobban F, Belousov M, Emsley R, Nenadic G, Bucci S . #WhyWeTweetMH: Understanding Why People Use Twitter to Discuss Mental Health Problems. J Med Internet Res. 2017; 19(4):e107. PMC: 5399219. DOI: 10.2196/jmir.6173. View

3.
Chen L, Baker T, Korpecki J, Johnson K, Hook J, Brownson R . Low-Burden Strategies to Promote Smoking Cessation Treatment Among Patients With Serious Mental Illness. Psychiatr Serv. 2018; 69(8):849-851. PMC: 6280191. DOI: 10.1176/appi.ps.201700399. View

4.
Ramsey A, Baker T, Stoneking F, Smock N, Chen J, Pham G . Increased Reach and Effectiveness With a Low-Burden Point-of-Care Tobacco Treatment Program in Cancer Clinics. J Natl Compr Canc Netw. 2022; 20(5):488-495.e4. PMC: 9173433. DOI: 10.6004/jnccn.2021.7333. View

5.
Morris Z, Wooding S, Grant J . The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011; 104(12):510-20. PMC: 3241518. DOI: 10.1258/jrsm.2011.110180. View